Climb Bio Financials
| CLYM Stock | 1.95 0.08 3.94% |
Investors should never underestimate Climb Bio's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Climb Bio's cash flow, debt, and profitability to make informed and accurate decisions about investing in Climb Bio.
Net Income |
|
Climb | Select Account or Indicator |
Understanding current and past Climb Bio Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Climb Bio's financial statements are interrelated, with each one affecting the others. For example, an increase in Climb Bio's assets may result in an increase in income on the income statement.
Climb Bio Stock Summary
Climb Bio competes with Dogwood Therapeutics,, Opus Genetics,, and Telix Pharmaceuticals. Climb Bio is entity of United States. It is traded as Stock on NASDAQ exchange.Specialization | Healthcare, Biotechnology |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| CUSIP | 28658R106 |
| Older Symbol | ELYM |
| Location | Washington; U.S.A |
| Business Address | PMB 117, 2801 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | eliemtx.com |
| Phone | 866 857 2596 |
Climb Bio Key Financial Ratios
| Net Income | (35.12 M) | ||||
| Total Asset | 110.47 M | ||||
| Retained Earnings | (155.98 M) |
Climb Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Climb Bio's current stock value. Our valuation model uses many indicators to compare Climb Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Climb Bio competition to find correlations between indicators driving Climb Bio's intrinsic value. More Info.Climb Bio is rated fifth in net income category among its peers. It is rated third in total debt category among its peers . Climb Bio reported last year Net Loss of (35.12 Million). Comparative valuation analysis is a catch-all technique that is used if you cannot value Climb Bio by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Climb Bio Systematic Risk
Climb Bio's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Climb Bio volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Climb Bio correlated with the market. If Beta is less than 0 Climb Bio generally moves in the opposite direction as compared to the market. If Climb Bio Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Climb Bio is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Climb Bio is generally in the same direction as the market. If Beta > 1 Climb Bio moves generally in the same direction as, but more than the movement of the benchmark.
Climb Bio December 20, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Climb Bio help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Climb Bio. We use our internally-developed statistical techniques to arrive at the intrinsic value of Climb Bio based on widely used predictive technical indicators. In general, we focus on analyzing Climb Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Climb Bio's daily price indicators and compare them against related drivers.
| Information Ratio | (0.40) | |||
| Maximum Drawdown | 20.92 | |||
| Value At Risk | (9.49) | |||
| Potential Upside | 5.92 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Climb Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.